The main result is that for the most common form of advanced breast cancer, adding ribociclib to letrozole significantly improved progression-free survival (PFS), as compared to adding a placebo.

Like Pfizer’s Ibrance (palbociclib), ribociclib is an inhibitor of cyclin ... The data showed LEE011 plus letrozole reduce risk of progression or death by 44% compared with letrozole alone ...

Additional analyses from the phase 3 MONALEESA-2 study that show ribociclib, codenamed LEE011, plus letrozole significantly prolonged progression-free survival (PFS) across pre-planned patient ...

Their research suggested that neoadjuvant therapy with a combination of ribociclib and letrozole could be an alternative to multi-drug neoadjuvant chemotherapy. The trial involved high risk ...

Participants were randomly assigned to either receive ribociclib plus endocrine therapy (2,549 patients), consisting of a nonsteroidal aromatase inhibitor or to receive endocrine therapy alone (2552 ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Recent clinical trial data suggested a new first-line ...

Kisqali ® (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 ...

has adopted a positive opinion and recommended granting marketing authorization for Kisqali ® (ribociclib) for the adjuvant treatment of adults with hormone receptor-positive/human epidermal ...

Ribociclib plus Endocrine Therapy in Early Breast Cancer ... from the Phase III MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with HR+/HER2− advanced breast ...

Kisqali® (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 ...